For research use only
| Cat No. | ABC-TC0179 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Large Cell Cancer |
| Product Code | CORL23; COR-L23P; COR-L23/P; L23/P |
COR-L23 human lung carcinoma cells from 62-year-old male show epithelial morphology,c-myc amplification,KRAS mutation, tumorigenic,ideal for lung cancer.
COR-L23 is a human non-small cell lung carcinoma (NSCLC) cell line that was originally established in 1985 from the pleural effusion of a 62-year-old Caucasian male patient diagnosed with giant cell anaplastic carcinoma of the lung. These adherent epithelial-like cells exhibit a polygonal morphology and can be continuously cultured and passaged in vitro. COR-L23 cells express typical lung epithelial markers, including cytokeratins, and display characteristics consistent with adenocarcinoma subtype of NSCLC. They harbor mutations and molecular alterations relevant to lung cancer pathogenesis, such as alterations in TP53, which contribute to their tumorigenic behavior. Their ability to form tumors in xenograft models makes them valuable for preclinical testing of anticancer therapies targeting lung adenocarcinoma.
| Product Code | CORL23; COR-L23P; COR-L23/P; L23/P |
| Species | Human |
| Cat.No | ABC-TC0179 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Large Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
COR-L23 is a human lung cancer cell line widely applied in drug development. It is used to evaluate the effects of interferons, such as alpha and recombinant gamma IFNs, on lung cancer cell growth. It also plays a critical role in studying the multidrug resistance-associated protein (MRP) gene, aiding in the development of therapies aimed at overcoming chemoresistance in lung tumors.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
